DALLAS, March 2, 2015 /PRNewswire/
--
ReportsnReports.com adds Lonsurf and Avastin (Colorectal Cancer)
- Forecast and Market Analysis to 2023 research report focuses on
the current treatment landscape, unmet needs, current pipeline, and
commercial opportunities in the colorectal cancer market.
Colorectal cancer (CRC) is the second leading cause of mortality
among cancer patients in the world and is the third most diagnosed
cancer globally, and thus represents a huge burden on healthcare
systems. This report focuses on the current treatment landscape,
unmet needs, current pipeline, and commercial opportunities in the
colorectal cancer market, with coverage of multiple settings of the
disease including neoadjuvant/adjuvant, first-, second-, third-line
KRAS wild-type and mutation-positive, and fourth-line metastatic.
In terms of targeted treatments, the metastatic CRC treatment
landscape is mature, including the branded treatments Avastin
(bevacizumab), Avastin (cetuximab), Erbitux (cetuximab), and
Vectibix (panitumumab), treatments that have extended the survival
of metastatic patients compared to chemotherapy-only regimens.
However, high unmet needs remain for the extension of survival of
metastatic patients, and particularly those with KRAS
mutation-positive disease, for whom the epidermal growth factor
receptor (EGFR) inhibitors Avastin, Erbitux and Vectibix are not
recommended.
The report "Lonsurf (Colorectal Cancer) - Forecast and Market
Analysis to 2023" focuses on the current treatment landscape, unmet
needs, current pipeline, and commercial opportunities in the
colorectal cancer market. Taiho Pharmaceutical's Lonsurf (TAS-102)
is an oral nucleoside antitumor drug which launched in 2014 for the
treatment of chemotherapy-refractive metastatic CRC in Japan. In May
2014, Taiho Pharmaceutical announced that the Phase III
RECOURSE trial met its primary outcome of OS and that the company
is preparing for regulatory submission in the US and Europe. In October
2014, Taiho announced that Lonsurf has received FDA
Fast-Track designation and had initiated rolling NDA submission.
This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory
approval for the treatment of recurrent unresectable locally
advanced or metastatic CRC in Japan based on Phase II data. Order a copy
of this report at (Prices start at US $
3495 for a single user
PDF) http://www.reportsnreports.com/purchase.aspx?name=320823
.
The report "Avastin (Colorectal Cancer) - Forecast and Market
Analysis to 2023" focuses on the current treatment landscape, unmet
needs, current pipeline, and commercial opportunities in the
colorectal cancer market, with coverage of multiple settings of the
disease including neoadjuvant/adjuvant, first-, second-, third-line
KRAS wild-type and mutation-positive, and fourth-line metastatic.
Avastin was the first agent of a new class of drugs that
targeted the angiogenesis pathway. The anti-angiogenic agent is a
humanized monoclonal IgG1 that binds to vascular endothelial growth
factor-A (VEGF-A), preventing the ligand from binding to the VEGF
receptor. Inhibition of the VEGF pathway prevents endothelial cells
from proliferating and forming the new bloods vessels that are
required for the tumor to grow. The drug delivered as a monotherapy
is not curative, and must be co-administered with a chemotherapy
regimen. Order a copy of this report at (Prices start at US
$ 3495 for a single user
PDF) http://www.reportsnreports.com/purchase.aspx?name=320815
.
Scope of these reports includes: Overview of Colorectal Cancer,
including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive
landscape; Detailed information on Lonsurf and Avastin including
product description, safety and efficacy profiles as well as a SWOT
analysis; Sales forecast for Lonsurf and Avastin for the top eight
countries from 2013 to 2023; Sales information covered for the US,
France, Germany, Italy, Spain,
the UK, Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most
likely to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and
in-depth analysis of Lonsurf performance
- Obtain sales forecast for Lonsurf from 2013-2023 in top eight
countries (the US, France,
Germany, Italy, Spain,
the UK, Japan and China)
Other Related Reports:
Erbitux (Colorectal Cancer) - Forecast and Market Analysis to
2023
In February 2004, Eli
Lilly/BMS/Merck KGaA's Erbitux (cetuximab) became the first
monoclonal antibody to be approved by the FDA for metastatic CRC.
The recombinant chimeric IgG1 monoclonal antibody was the first of
a novel class of antibodies that target the EGFR pathway.
Overexpression of the epidermal growth factor receptor (EGFR, HER1,
c-ErbB-1) is frequent in CRC, where it contributes to activate
genes that drive the cell cycle and mitosis. The binding of Erbitux
to EGFR inhibits the downstream signaling of the receptor and hence
reduces tumor progression and initiates cell cycle arrest. Complete
report details available @
http://www.reportsnreports.com/reports/320824-erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023.html
.
Vectibix (Colorectal Cancer) - Forecast and Market Analysis
to 2023
Amgen/Takeda's EGFR antagonist Vectibix (panitumumab) was
approved in the US in 2006 as a monotherapy for
chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic
CRC. EU approval followed in 2007, where the agent is also
indicated as a treatment for chemotherapy-refractory KRAS wild-type
CRC patients, however, EGFR-expression is not specified.
Additionally in the EU, the antibody is approved in combination
with FOLFOX in the first-line setting, and with FOLFIRI in the
second-line setting after progression on a 5-FU regimen. Complete
report details available @
http://www.reportsnreports.com/reports/320816-vectibix-colorectal-cancer-forecast-and-market-analysis-to-2023.html
.
Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to
2023
In 2012, Sanofi/Regeneron's Zaltrap (ziv-aflibercept) was
approved by the FDA in combination with FOLFIRI for the treatment
of metastatic CRC that has become resistant or progressed on prior
oxaliplatin-containing combination therapy (FDA, press release,
August 3, 2012). This was followed by
European approval in February 2013
(Sanofi and Regeneron, press release, February 5, 2013). Complete report details
available @
http://www.reportsnreports.com/reports/320819-zaltrap-colorectal-cancer-forecast-and-market-analysis-to-2023.html
.
About Us:
ReportsnReports.com is an online market research reports library
of 500,000+ reports and in-depth studies of 5000+ micro markets. We
provide reports by 100+ publishers on a range of categories and
industries.
Connect with Us:
G+ / Google
Plus: https://plus.google.com/u/0/111656568937629536321/posts
Twitter: http://twitter.com/marketsreports
Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
RSS /
Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion
Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com